THE PLEIOTROPIC ACTION OF SHORT-TERM METFORMIN AND FENOFIBRATE TREATMENT, COMBINED WITH LIFESTYLE INTERVENTION, IN TYPE 2 DIABETIC PATIENTS WITH MIXED DYSLIPIDEMIA
- Maciej Pruski, MD,
- Robert Krysiak, MD (r.krysiak{at}interia.pl) and
- Boguslaw Okopien, MD, PhD
- Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, PL 40-752 Katowice, Poland. Tel/fax number: +48 32 2088512
Abstract
Objective: To compare the effect of short-term metformin and fenofibrate treatment, administered alone or in sequence, on glucose and lipid metabolism, cardiovascular risk factors and monocyte cytokine release in type 2 diabetic patients with mixed dyslipidemia.
Research Design and Methods: We studied 128 type 2 diabetes patients with mixed dyslipidemia complying throughout the study with lifestyle intervention who were randomized twice, initially to either metformin or placebo and then to micronized fenofibrate or placebo.
Results: Fenofibrate alleviated diabetic dyslipidemia-induced changes in plasma hsCRP, fibrinogen and PAI-1, and in monocyte cytokine release, while metformin or lifestyle intervention improved mainly glucose and lipid metabolism. The strongest pleiotropic effect was observed when fenofibrate was added to metformin.
Conclusions: Fenofibrate, particularly administered together with metformin, is superior to metformin and lifestyle intervention in exhibiting beneficial effects on systemic inflammation, hemostasis and monocyte secretory function in type 2 diabetic patients with mixed dyslipidemia.
Footnotes
-
- Received December 30, 2008.
- Accepted April 27, 2009.
- Copyright © American Diabetes Association
